250 related articles for article (PubMed ID: 30204504)
21. Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Fukae J; Nakamura R; Kurita N; Tsunemi T; Oji Y; Saiki S; Nishioka K; Takeshige-Amano H; Taniguchi D; Ogawa T; Kamo H; Eguchi H; Fuse A; Nakajima A; Kano M; Nakajima S; Yanagisawa N; Hattori N
BMJ Open; 2022 Feb; 12(2):e054129. PubMed ID: 35149566
[TBL] [Abstract][Full Text] [Related]
22. Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
Eguchi T; Yoshizaki T; Ikeoka S; Takagi M; Fujinami M; Matsuda T; Yamaguchi T; Nonaka T; Amioka S; Katayama N; Inoue K; Matsumoto M; Momose K; Sako T; Noda M; Morisawa T; Okada A
Dig Dis; 2021; 39(4):341-350. PubMed ID: 33142288
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST-PD Study.
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Nakamura R; Tsunemi T; Ogawa T; Eguchi H; Daida K; Kurita N; Ueno SI; Fukae J; Sako W; Shiina K; Nakajima S; Oji Y; Wakamori R; Saiki S; Nishioka K; Okuzumi A; Taniguchi D; Takeshige-Amano H; Fuse A; Nakajima A; Kano M; Kamo H; Yamashita Y; Shindo A; Yanagisawa N; Hattori N
Mov Disord Clin Pract; 2024 Apr; 11(4):352-362. PubMed ID: 38264844
[TBL] [Abstract][Full Text] [Related]
24. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.
Chey WD; Camilleri M; Chang L; Rikner L; Graffner H
Am J Gastroenterol; 2011 Oct; 106(10):1803-12. PubMed ID: 21606974
[TBL] [Abstract][Full Text] [Related]
25. Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
Ozaki A; Kessoku T; Kasai Y; Takeda Y; Okubo N; Iwaki M; Kobayashi T; Yoshihara T; Honda Y; Fuyuki A; Higurashi T; Ishiki H; Taguri M; Oyamada S; Kobayashi N; Nakajima A; Ichikawa Y
Oncologist; 2021 Oct; 26(10):e1862-e1869. PubMed ID: 34180099
[TBL] [Abstract][Full Text] [Related]
26. Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM.
Yoshinobu S; Hasuzawa N; Nagayama A; Iwata S; Yasuda J; Tokubuchi R; Kabashima M; Gobaru M; Hara K; Murotani K; Moriyama Y; Ashida K; Nomura M
Clin Ther; 2022 Oct; 44(10):1418-1426. PubMed ID: 36117045
[TBL] [Abstract][Full Text] [Related]
27. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Ooba N; Takahashi Y; Nagamura M; Takahashi M; Ushida M; Kawakami E; Kimura M; Sato T; Tokuyoshi J; Miyazaki C; Shimada M
Expert Opin Drug Saf; 2021 Dec; 20(12):1553-1558. PubMed ID: 34281471
[TBL] [Abstract][Full Text] [Related]
28. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
29. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
[TBL] [Abstract][Full Text] [Related]
30. New pharmacological treatment options for irritable bowel syndrome with constipation.
Nusrat S; Miner PB
Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
[TBL] [Abstract][Full Text] [Related]
31. [Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)].
Ichihashi T
Nihon Rinsho; 2002 Jan; 60(1):130-6. PubMed ID: 11808323
[TBL] [Abstract][Full Text] [Related]
32. The role of bile acids in functional GI disorders.
Appleby RN; Walters JR
Neurogastroenterol Motil; 2014 Aug; 26(8):1057-69. PubMed ID: 24898156
[TBL] [Abstract][Full Text] [Related]
33. Altered bile acid pool using IBAT inhibitors for constipation: a potentially increased risk of malignancy.
Trivedi PJ; Ward S
Am J Gastroenterol; 2012 Jan; 107(1):140; author reply 140-1. PubMed ID: 22218036
[No Abstract] [Full Text] [Related]
34. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.
Shin A; Camilleri M; Vijayvargiya P; Busciglio I; Burton D; Ryks M; Rhoten D; Lueke A; Saenger A; Girtman A; Zinsmeister AR
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1270-1275.e1. PubMed ID: 23639599
[TBL] [Abstract][Full Text] [Related]
35. Methods for diagnosis of bile acid malabsorption in clinical practice.
Vijayvargiya P; Camilleri M; Shin A; Saenger A
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1232-9. PubMed ID: 23644387
[TBL] [Abstract][Full Text] [Related]
36. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea.
Vijayvargiya P; Camilleri M; Chedid V; Carlson P; Busciglio I; Burton D; Donato LJ
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):922-929.e2. PubMed ID: 29902647
[TBL] [Abstract][Full Text] [Related]
38. Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion.
Camilleri M; Shin A; Busciglio I; Carlson P; Acosta A; Bharucha AE; Burton D; Lamsam J; Lueke A; Donato LJ; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2014 Sep; 307(5):G508-16. PubMed ID: 25012842
[TBL] [Abstract][Full Text] [Related]
39. Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption.
Peleman C; Camilleri M; Busciglio I; Burton D; Donato L; Zinsmeister AR
Clin Gastroenterol Hepatol; 2017 May; 15(5):720-727.e1. PubMed ID: 27856362
[TBL] [Abstract][Full Text] [Related]
40. Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples.
Vijayvargiya P; Busciglio I; Burton D; Donato L; Lueke A; Camilleri M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):522-527. PubMed ID: 28666948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
